Systemic Juvenile Idiopathic Arthritis (sJIA)
Systemic Juvenile Idiopathic Arthritis (sJIA) is a rare type of arthritis that affects children, characterized by joint inflammation and systemic symptoms such as fever and rash.
Systemic Juvenile Idiopathic Arthritis: Sarilumab Study
We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 1 and 17 years old?
- Do you have systemic juvenile idiopathic arthritis (sJIA)?
- Is your body weight between 10 kg and 60 kg?
- Are you pregnant or breastfeeding?
- Have you been stable on your current medications for at least 2 weeks?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
University Multiprofile Hospital For Active Treatment Saint Georgi EAD
Pediatric Clinic
Plovdiv, Bulgaria
Meilahti Hospital
Hematology
Helsinki, Finland
Hospices Civils De Lyon
Service de Nephrologie, Rhumatologie et dermatologie Pediatriques
Bron, France
Sponsor: Sanofi-Aventis Recherche & Developpement
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.